萬邦德(002082.SZ):鹽酸溴己新注射液獲批上市
格隆匯11月29日丨萬邦德(002082.SZ)公佈,2022年11月29日,公司全資子公司萬邦德製藥集團有限公司(“萬邦德製藥”)收到國家藥品監督管理局關於鹽酸溴己新注射液的《藥品註冊證書》,證書號為:2022S01140。
鹽酸溴己新注射液為2021版國家醫保目錄品種,本品有較強的溶解黏痰作用,可使痰中的多糖纖維素裂解,稀化痰液。抑制杯狀細胞和黏液腺體合成糖蛋白,使痰液中的唾液酸減少,降低痰黏度,便於排出。本品尚有促進呼吸道黏膜的纖毛運動作用。主要用於在口服給藥困難的情況下,慢性支氣管炎及其他呼吸道疾病如哮喘、支氣管擴張、矽肺等有粘痰不易咳出的患者。
根據米內網數據,2021年鹽酸溴己新注射劑在公立醫療機構的銷售額為12.36億元。
鹽酸溴己新注射液註冊證書的取得,豐富公司呼吸系統領域的產品線,主要產品包括鹽酸溴己新原料藥、鹽酸溴己新片、鹽酸溴己新注射液、鹽酸氨溴索注射液,更加凸顯公司原料藥+製劑優勢,對公司經營發展也具有一定的積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.